茵栀黄口服液对非酒精性脂肪性肝炎大鼠肝脂肪变的保护作用研究

Effects of Yinzhihuang oral solution on steatosis in rat with MCD-induced non-alcoholic steatohepatitis

目的探讨茵栀黄口服液对蛋氨酸胆碱缺乏(MCD)饮食诱导的非酒精性脂肪性肝炎(NASH)大鼠肝脂肪变的保护作用。方法将30只大鼠随机均分为对照组、MCD组和茵栀黄灌胃组。给予对照组普通饮食,给予另两组动物MCD饮食,于第4周末开始分别给予生理盐水或茵栀黄口服液灌胃,第8 w末处死大鼠。取肝组织行病理学检查。取血,使用全自动生化分析仪检测大鼠血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、空腹血糖(FBG)。结果对照组和MCD组大鼠体质量分别为【(487.2±6.5)g和(155.8±3.1)g,P<0.05】,肝指数分别为【(2.92±0.06)%和(5.09±0.19)%,P<0.05】;MCD组大鼠肝组织出现明显的肝脏脂肪变、小叶炎症和气球样变,同时伴有轻度纤维化,茵栀黄处理组大鼠肝指数为(4.47±0.18)%,显著低于MCD组(P<0.05);茵栀黄组和MCD组大鼠肝组织NAFLD活动度积分(NAS)分别为【(5.9±0.2)分和(7.2±0.1)分,P<0.05】,肝纤维化积分为【(0.3±0.2)分和(0.8±0.2)分,P<0.05】;茵栀黄组和MCD组大鼠血清ALT水平分别为【(68.4±6.4)U/L和(111.9±5.5)U/L,P<0.05】,AST分别为【(110.5±7.9)U/L和(170.5±10.8)U/L,P<0.05】,但是茵栀黄口服液灌胃对MCD大鼠血脂和血糖无显著影响。结论茵栀黄口服液可以改善MCD诱导的NASH大鼠肝脏脂肪变、肝细胞气球样变、小叶炎症和纤维化,降低NASH大鼠血清转氨酶水平,为应用茵栀黄口服液处理NAFLD提供了实验依据。

Objective To explore the effects of Yinzhihuang oral solution on steatosis in rats withmethionine and choline deficient diet （MCD） -induced non-alcoholic steatohepatitis （NASH） . Methods 30 malerats were randomly divided into control, MCD, and Yinzhihuang-intervened group. The animals in control group wasgivena standard diet, and those in MCD and Yinzhihuang group were given MCD diet. At the end of forth week,saline or Yinzhihuang oral solution were administered intragastricly,respectively, once a day for four weeks. Theliver tissues was obtained for HE and Masson staining and histological analysis was examined by NAFLD activityscore（NAS）system, and the blood was analyzed for biochemical parameters. Results The body weight of rats incontrol and MCD group were [ （487.2±6.5） g and（155.8±3.1） g, P〈0.05], and the liver index were [ （2.92±0.06）%and（5.09±0.19） %, P〈0.05]; the liver tissues in MCD group showed obvious hepatic steatosis, lobular inflammation,and ballooning of hepatocytes with mild fibrosis; the liver index in Yinzhihuang group [ （4.47±0.18） %] was lowerthan that in MCD group（P〈0.05）; the NAS scores in Yinzhihuang group and MCD group were 5.9±0.2 and 7.2±0.1（P〈0.05）, and the fibrosis score were 0.3±0.2 and0.8 ±0.2 （P〈0.05）; serum ALT levels in Yinzhihuanggroup and MCD group were [ （68.4 ±6.4） U/L and（111.9±5.5） U/L, P〈0.05], and AST levels were[ （110.5±7.9） U/L and （170.5 ±10.8） U/L, P 〈0.05], while serumTBIL, TG, TC, LDL, HDL, and FBG had no significantdifference between Yinzhihuang group and MCD group.Conclusion Yinzhihuang oral solution could improvehepatic steatosis,lobular inflammation, ballooning, andfibrosis in liver tissues, suggesting its therapeutic effects on NASH in animal models.